Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving TolvaptanKiyotaka Uchiyama, Kaori Hayashi, Takaya Tajima et al.|Kidney International Reports|2025Cited by 16
Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case seriesDaiki Kojima, Hiroshi Itoh, Shintaro Yamaguchi et al.|Frontiers in Medicine|2023Cited by 1
PS-C18-3: RENIN-ANGIOTENSIN SYSTEM INHIBITORS IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE ASSOCIATED WITH A LOWER RISK OF UNPLANNED DIALYSIS INITIATIONTakashin Nakayama, Hiroshi Itoh, Kohkichi Morimoto et al.|Journal of Hypertension|2023Cited by 0
Effective calcineurin inhibitor treatment in adult-onset steroid-resistant nephrotic syndrome with a novel splice donor site variant of TRPC6: a case reportTomoki Nagasaka, Hiroshi Itoh, Kiyotaka Uchiyama et al.|CEN Case Reports|2024Cited by 0
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]Kiyotaka Uchiyama, Kaori Hayashi, Daisuke Kamano et al.|Kidney International Reports|2025Cited by 0